Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19

  • Ann Clin Microbiol Antimicrob. 2020 May 30;19(1):23. doi: 10.1186/s12941-020-00368-w.
Khan Sharun  1 ,  Kuldeep Dhama  2 ,  Shailesh Kumar Patel  3 ,  Mamta Pathak  3 ,  Ruchi Tiwari  4 ,  Bhoj Raj Singh  5 ,  Ranjit Sah  6 ,  D Katterine Bonilla-Aldana  7  8 ,  Alfonso J Rodriguez-Morales  9  10 ,  Hakan Leblebicioglu  11
Affiliations
  • 1. Division of Surgery, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, 243 122, Uttar Pradesh, India.
  • 2. Division of Pathology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, 243 122, Uttar Pradesh, India. [email protected].
  • 3. Division of Pathology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, 243 122, Uttar Pradesh, India.
  • 4. Department of Veterinary Microbiology and Immunology, College of Veterinary Sciences, UP Pandit Deen Dayal Upadhayay Pashu Chikitsa Vigyan Vishwavidyalay Evum Go-Anusandhan Sansthan (DUVASU), Mathura, 281001, India.
  • 5. Division of Epidemiology, ICAR-Indian Veterinary Research Institute, Izatnagar, Bareilly, 243 122, Uttar Pradesh, India.
  • 6. Department of Microbiology, Institute of Medicine, Tribhuvan University Teaching Hospital, Kathmandu, Nepal.
  • 7. Semillero de Zoonosis, Grupo de Investigación BIOECOS, Fundación Universitaria Autónoma de las Américas, Sede Pereira, Pereira, Risaralda, Colombia.
  • 8. Public Health and Infection Research Group, Faculty of Health Sciences, Universidad Tecnologica de Pereira, Pereira, Colombia.
  • 9. Public Health and Infection Research Group, Faculty of Health Sciences, Universidad Tecnologica de Pereira, Pereira, Colombia. [email protected].
  • 10. Faculty of Medicine, Grupo de Investigacion Biomedicina, Fundacion Universitaria Autonoma de las Americas, Pereira, Risaralda, Colombia. [email protected].
  • 11. Department of Infectious Diseases, Samsun Liv Hospital, Samsun, Turkey.
PMID: 32473642 DOI: 10.1186/s12941-020-00368-w
Keywords
2019-nCoV; COVID-19; Coronavirus; Ivermectin; SARS-CoV-2; Therapeutics.
Products